SAI Life Sciences Ltd. (IN:SAILIFE)
:SAILIFE
Want to see IN:SAILIFE full AI Analyst Report?
SAILIFE Stock Chart & Stats
₹1010.25
₹4.05(0.56%)
At close: 4:00 PM EST
₹1010.25
₹4.05(0.56%)
Day’s Range― - ―
52-Week Range₹704.45 - ₹1,151.00
Previous CloseN/A
Volume67.81K
Average Volume (3M)11.95K
Market Cap
₹241.96B
Enterprise Value₹243.76B
Total Cash (Recent Filing)₹3.06B
Total Debt (Recent Filing)₹5.64B
Price to Earnings (P/E)58.4
Beta1.11
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.01
Shares Outstanding212,023,150
10 Day Avg. Volume10,862
30 Day Avg. Volume11,945
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)8.20
Price to Sales (P/S)9.29
P/FCF Ratio-282.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,270.00Price Target Upside25.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)19.54
Revenue Forecast (FY)₹26.60B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin MomentumVery strong top-line growth and expanding operating profitability indicate the business is scaling with operational leverage. Sustained double-digit net and high-20s EBITDA margins point to durable profit economics as projects move from discovery to higher-value development and manufacturing.
Conservative Balance SheetLow leverage and improving return on equity provide financial flexibility to fund capex, capacity expansion or selective M&A without materially increasing solvency risk. A conservative capital structure supports resilience through pharma cycle volatility and underpins long-term investment capability.
Integrated CRDMO Business ModelOffering end-to-end discovery-to-manufacture services creates multi-year client touchpoints and cross-sell opportunities, improving program retention and revenue visibility. Structural industry trend toward outsourcing favors scale players with integrated capabilities and repeat-program economics.
Bears Say
Persistent Negative Free Cash FlowDespite strong accounting profits, the company has produced negative free cash flow in consecutive years. Persistent FCF deficits can force external financing, constrain organic funding for capacity or R&D, and increase vulnerability if revenue growth or margins decelerate.
Poor Cash Conversion TrendWorsening free cash flow growth and negative conversion versus net income signal working-capital absorption or heavy capex needs. This undermines the durability of earnings and can lengthen payback on investments, pressuring liquidity and capital allocation over the medium term.
Gross Margin PressureA decline in gross margin, if persistent, indicates rising input costs or constrained pricing power, which can cap ultimate operating margin expansion. Even with operating leverage, sustained gross margin erosion would limit long-term profitability and return improvement.
SAI Life Sciences Ltd. News
SAILIFE FAQ
What was SAI Life Sciences Ltd.’s price range in the past 12 months?
SAI Life Sciences Ltd. lowest stock price was ₹704.45 and its highest was ₹1151.00 in the past 12 months.
What is SAI Life Sciences Ltd.’s market cap?
SAI Life Sciences Ltd.’s market cap is ₹241.96B.
When is SAI Life Sciences Ltd.’s upcoming earnings report date?
SAI Life Sciences Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 76 days.
How were SAI Life Sciences Ltd.’s earnings last quarter?
SAI Life Sciences Ltd. released its earnings results on May 14, 2026. The company reported ₹4.9 earnings per share for the quarter, missing the consensus estimate of ₹5.1 by -₹0.2.
Is SAI Life Sciences Ltd. overvalued?
According to Wall Street analysts SAI Life Sciences Ltd.’s price is currently Undervalued.
Does SAI Life Sciences Ltd. pay dividends?
SAI Life Sciences Ltd. does not currently pay dividends.
What is SAI Life Sciences Ltd.’s EPS estimate?
SAI Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SAI Life Sciences Ltd. have?
SAI Life Sciences Ltd. has 212,023,150 shares outstanding.
What happened to SAI Life Sciences Ltd.’s price movement after its last earnings report?
SAI Life Sciences Ltd. reported an EPS of ₹4.9 in its last earnings report, missing expectations of ₹5.1. Following the earnings report the stock price went up 2.42%.
Which hedge fund is a major shareholder of SAI Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SAILIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAI Life Sciences Ltd.
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
SAILIFE Stock 12 Month Forecast
Average Price Target
₹1,270.00
▲(25.71% Upside)
Technical Analysis
Indoco Remedies Limited
―
Indraprastha Medical Corporation Limited
―
Kopran Limited
―
SMS Pharmaceuticals Limited
―
Zota Health Care Ltd.
―